We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Growth Seen for European POC Coagulation Testing

By HospiMedica staff writers
Posted on 15 Dec 2003
The point-of-care (POC) testing market in Europe will grow from 140 million euros in 2003 to more than 350 million euros in 2009, according to a new analysis from international consultants Frost & Sullivan (London, UK). This figure includes near-testing and self-testing devices. The growth is being fostered by the clinical results and the lower costs of an increasing number of outpatient anticoagulation clinics.

POC coagulation analyzers are gaining preference in the critical care, surgery, and home testing environments, since they provide rapid and accurate information for improved patient monitoring. Coagulation testing looks at endpoint measurements between bleeding and clotting, and the new technologic developments are expected to allow a comprehensive assessment of the complex interactions between various blood clotting factors.

"The biggest advantage of POC testing is the decrease in turn-around time because most POC analyses are performed on whole blood, minimizing any transport and logistic handovers that normally occur within laboratory testing,” explained Shree Viswadia, a research analyst with Frost & Sullivan.

Market concerns include slow implementation of insurance reimbursement and the development of new thrombin inhibitor drugs that could gradually eliminate the need for routine testing. Nonetheless, POC testing is finding increasing acceptance across Europe, with Germany, Italy, and the United Kingdom having the largest number of users.




Related Links:
Frost & Sullivan >>

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit

Latest Industry News

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
15 Dec 2003  |   Industry

Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
15 Dec 2003  |   Industry

New Collaboration to Advance Microbial Identification for Infectious Disease Diagnostics
15 Dec 2003  |   Industry